MabDesign’s market analyses give you a monthly overview of market dynamics and projects in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month, an overview of the bispecific antibody market, as well as projects currently in the development pipeline.
Unlike conventional monoclonal antibodies, bispecific antibodies are able to target two different antigens, increasing their efficacy and specificity. This approach makes it possible, for example, to recruit immune cells directly in contact with tumor cells, or to combine different signaling pathways for enhanced therapeutic effect.
Given the vast therapeutic possibilities they offer, the bispecific antibody market is experiencing rapid growth, underpinned by technological advances and significant investment in research and development.
Twelve bispecific antibodies are currently on the market, the majority targeting oncology indications. Of these products, 67% have indications in liquid tumors (blood cancers), and 75% are bispecific T-cell engagers.
bispecific antibodies market
67%
indicated in liquid tumors
75%
bispecific T cell engagers
The overall development pipeline is very rich, with 387 products currently in clinical phase. Thirteen products are currently in pre-registration and could soon be on the market. Since 2017, the number of clinical trials for bispecific antibodies has been rising steadily. This trend demonstrates a strong development momentum that is set to continue, particularly in oncology, where the majority of products are concentrated.
number of clinical trials
Bispecific antibodies in clinical phases
The products in the pipeline, like those already on the market, are mainly in the field ofoncology : there are nevertheless 52 products in clinical phase targeting other indications. The enthusiasm generated by T cell engagers is also reflected in the pipeline, with the top molecules targeted by products in development: the CD3 receptor, involved in T cell activation, tops the list.
Finally, the presence of 17 bispecific ADCs in the clinical phase is a notable technological trend. Indeed, these therapeutic tools offer interesting prospects by combining the cytotoxicity of ADCs with the specificity of bispecific antibodies.
Top targets (pipeline)
Pipeline trends
Want to find out more?
To find out more, join us on June 20 and 21, 2024 in Montpellier for the 12th edition of our Antibody Industrial Symposium (AIS2024)! You canregisternow, or contact us for more information.
MabDesign has acquired and cultivates its expertise in all market segments associated with biopharmaceuticals and biomanufacturing. Our team of consultants is at your disposal to support you in all your biotherapy-related projects. Feel free to explore our range of services, including our marketing and strategic analyses, if you’d like to find out more!
Sources: MabDesign & GlobalData
Date – May 2024
